![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Extract
Allan Murphy (this issue; Murphy, 2001) presents an argument, based on our recent article in this journal (Leathwick et al, Citation2000), designed to convince the reader that moxidectin is superior to abamectin at controlling ivermectin-resistant parasites and should therefore be the macrocyclic lactone anthelmintic of choice in this country. His letter, however, fails to adequately address several important issues.